Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Tumor Growth Rate (TGR) Analysis Predicts Survival in a Multicenter Phase II Study of the PARP Inhibitor Pamiparib (BGB-290) with Temozolomide in Recurrent IDH-Mutant Gliomas (ABTC-1801).

AJNR. American journal of neuroradiology·2026
Same author

NAPRT expression and epigenetic regulation in pediatric rhabdomyosarcoma as a potential biomarker for NAMPT inhibition.

Molecular cancer therapeutics·2026
Same author

Patterns and Clinical Outcomes of Physical Activity and Sedentary Behavior Across 20 Million Days of Wearable Monitoring in U.S. Adults.

medRxiv : the preprint server for health sciences·2026
Same author

Targeted CRISPR knockout screening identifies known and novel chemogenomic interactions between DNA damaging agents and DNA repair genes.

NAR cancer·2026
Same author

Mismatch repair deficiency drives malignant progression and alters the tumor immune microenvironment in glioblastoma models.

The Journal of clinical investigation·2025
Same author

Synthesis and Biological Evaluation of Colibactin Derivatives.

ACS chemical biology·2025

Related Experiment Video

Updated: Jul 13, 2026

Multiparametric Tumor Organoid Drug Screening Using Widefield Live-Cell Imaging for Bulk and Single-Organoid Analysis
12:41

Multiparametric Tumor Organoid Drug Screening Using Widefield Live-Cell Imaging for Bulk and Single-Organoid Analysis

Published on: December 23, 2022

CellPyAbility: automated image analysis for high-throughput dose-response screening.

James L Elia1, Sam Friedman2, Ranjit S Bindra2

  • 1Department of Pathology, Yale School of Medicine, New Haven, CT United States.

Bioinformatics (Oxford, England)
|July 11, 2026
PubMed
Summary

CellPyAbility offers a streamlined, Python-based solution for nuclei counting, providing a cost-effective cell viability assay alternative. This automated tool simplifies image processing and analysis for high-throughput drug screening.

More Related Videos

Expedited Radiation Biodosimetry by Automated Dicentric Chromosome Identification (ADCI) and Dose Estimation
10:33

Expedited Radiation Biodosimetry by Automated Dicentric Chromosome Identification (ADCI) and Dose Estimation

Published on: September 4, 2017

High-Content Screening Assay for the Identification of Antibody-Dependent Cellular Cytotoxicity Modifying Compounds
13:59

High-Content Screening Assay for the Identification of Antibody-Dependent Cellular Cytotoxicity Modifying Compounds

Published on: August 18, 2023

Related Experiment Videos

Last Updated: Jul 13, 2026

Multiparametric Tumor Organoid Drug Screening Using Widefield Live-Cell Imaging for Bulk and Single-Organoid Analysis
12:41

Multiparametric Tumor Organoid Drug Screening Using Widefield Live-Cell Imaging for Bulk and Single-Organoid Analysis

Published on: December 23, 2022

Expedited Radiation Biodosimetry by Automated Dicentric Chromosome Identification (ADCI) and Dose Estimation
10:33

Expedited Radiation Biodosimetry by Automated Dicentric Chromosome Identification (ADCI) and Dose Estimation

Published on: September 4, 2017

High-Content Screening Assay for the Identification of Antibody-Dependent Cellular Cytotoxicity Modifying Compounds
13:59

High-Content Screening Assay for the Identification of Antibody-Dependent Cellular Cytotoxicity Modifying Compounds

Published on: August 18, 2023

Area of Science:

  • Biotechnology
  • Computational Biology
  • Drug Discovery

Background:

  • Cell viability assays are crucial for drug discovery and development.
  • Current methods like ATP- or tetrazolium-based assays have limitations.
  • Nuclei counting presents a metabolically independent and potentially lower-cost alternative.

Purpose of the Study:

  • To address the fragmentation and complexity of current nuclei counting image analysis pipelines.
  • To develop an automated, user-friendly software suite for high-throughput cell viability assessment.
  • To facilitate dose-response and synergy analysis from raw image data.

Main Methods:

  • Development of CellPyAbility, a Python-based software suite.
  • Automation of image processing, normalization, and statistical modeling for nuclei counting.
  • Integration of dose-response fitting and synergy analysis functionalities.

Main Results:

  • CellPyAbility automates the conversion of whole-well images into publication-ready graphics.
  • The suite processes a 96-well plate in under one minute on standard hardware.
  • It provides a unified platform for image analysis, dose-response fitting, and synergy analysis.

Conclusions:

  • Nuclei counting, when automated by CellPyAbility, is a viable, low-cost alternative to traditional cell viability assays.
  • CellPyAbility overcomes previous limitations by integrating image processing, normalization, and statistical analysis.
  • The software enables efficient high-throughput adoption of nuclei counting for drug discovery research.